A fresh look at tumor immunosurveillance and immunotherapy

Nature Immunology

Volumn 2, Issue 4, 2001, Pages 293-299

  Smyth, Mark J ^a   Godfrey, Dale I ^b   Trapani, Joseph A ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b MONASH UNIVERSITY MEDICAL SCHOOL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; TUMOR ANTIGEN;

ANIMAL; BIOLOGICAL MODEL; CELL TRANSFORMATION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; MOUSE; NEOPLASM; PATHOGENICITY; REVIEW; TUMOR VIRUS;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC SURVEILLANCE; IMMUNOTHERAPY; MICE; MODELS, BIOLOGICAL; NEOPLASMS; ONCOGENIC VIRUSES;

EID: 0035320526     PISSN: 15292908     EISSN: None     Source Type: Journal    
DOI: 10.1038/86297     Document Type: Review

References (85)

1. Coley, W. B. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am. J. Med. Sci. 105, 487-511 (1893).
2. Burnet, F. M. Cancer: a biological approach. Br. Med J. 1, 779-786 (1957).
3. Burnet, F. M. Immunological aspects of malignant disease. Lancet 1, 1171-1174 (1967).
4. Ada, G. The coming of age of tumour immunotherapy. Immunol. Cell Biol. 77, 180-185 (1999).
5. Stutman, O. Immunodepression and malignancy. Adv. Cancer Res. 22, 261-422 (1975).
6. Medzhitov, R. & Janeway, C. Jr Innate immune recognition: mechanisms and pathways. Immunol. Rev. 173, 89-97 (2000).
7. Fuchs, E. J. & Matzinger, P. Is cancer dangerous to the immune system? Semin. Immunol. 8, 271-280 (1996).
8. Gallucci, S., Lolkema, M. & Matzinger, P. Natural adjuvants: endogenous activators of dendritic cells. Nature Med. 5, 1249-1255 (1999).
9. Gallucci, S. & Matzinger, P. Danger signals: SOS to the immune system. Curr. Opin. Immunol. 13, 114-119 (2001).
10. Matzinger, P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12, 991-1045 (1994).
11. Bennett, S. R. et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393, 478-480 (1998).
12. Ridge, J. P., Fuchs, E. J. & Matzinger, P. Neonatal tolerance revisited: turning on newborn T cells with dendritic cells. Science 271, 1723-1726 (1996).
13. Schoenberger, S. P., Toes, R. E., van der Voort, E. I., Offringa, R. & Melief, C. J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393, 480-483 (1998).
14. Rosenberg, S. A. et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med. 4, 321-327 (1998).
15. Marchand, M. et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int. J. Cancer 63, 883-885 (1995).
16. Jager, E., Jager, D. & Knuth, A. CTL-defined cancer vaccines: perspectives for active immunotherapeutic interventions in minimal residual disease. Cancer Metastasis Rev. 18, 143-150 (1999).
17. Van den Eynde, B. J. & van der Bruggen, P. T cell defined tumor antigens. Curr. Opin. Immunol. 9, 684-693 (1997).
18. Wang, R. F. & Rosenberg, S. A. Human tumor antigens for cancer vaccine development. Immunol. Rev. 170, 85-100 (1999).
19. Houghton, A. N. Cancer antigens: immune recognition of self and altered self. J. Exp. Med. 180, 1-4. (1994).
20. Wolfel, T. et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269, 1281-1284 (1995).
21. Rickinson, A. B. & Moss, D. J. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu. Rev. Immunol. 15, 405-431 (1997).
22. Pfreundschuh, M. Exploitation of the B cell repertoire for the identification of human tumor antigens. Cancer Chemother. Pharmacol. 46, 3-7 (2000).
23. Robert, J. & Cohen, N. Evolution of immune surveillance and tumor immunity: studies in Xenopus. Immunol. Rev. 166, 231-243 (1998).
24. Groh, V. et al. Cell stress-regulated human major histocompatibitity complex class I gene expressed in gastrointestinal epithelium. Proc. Natl. Acad. Sci. USA 93, 12445-12450 (1996).
25. Groh, V., Steinle, A., Bauer, S. & Spies, T. Recognition of stress-induced MHC molecules by intestinal epithelial γδ T cells. Science 279, 1737-1740 (1998).
26. Diefenbach, A., Jamieson, A. M., Liu, S. D., Shastri N. & Raulet, D. H. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nature Immunol. 1, 119-126 (2000).
27. Cerwenka, A. et al. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 12, 721-727 (2000).
28. Bauer, S. et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285, 727-729 (1999).
29. Whiteside, T. L. & Herberman, R. B. The role of natural killer cells in immune surveillance of cancer. Curr. Opin. Immunol. 7, 704-710 (1995).
30. Godfrey, D. I., Hammond, K. J., Poulton, L. D., Smyth, M. J. & Baxter, A. G. NKT cells: facts, functions and fallacies. Immunol. Today 21, 573-583 (2000).
31. Smyth, M. J. & Godfrey, D. I. NKT cells and tumor immunity: a double edged sword. Nature Immunol. 1, 459-460 (2000).
32. Lanier, L. L. NK cell receptors. Annu. Rev. Immunol. 16, 359-393 (1998).
33. Salcedo, M. Inhibitory role of murine Ly49 lectin-like receptors on natural killer cells. Curr. Top. Microbiol. Immunol. 244, 97-105 (1999).
34. Takei, F., Brennan, J. & Mager, D. L. The Ly 49 family: genes, proteins and recognition of class I MHC. Immunol. Rev. 155, 67-77 (1997).
35. Lopez-Botet, M., Llano, M., Navarro, F. & Bellon, T. NK cell recognition of non-classical HLA class I molecules. Semin. Immunol. 12, 109-119 (2000).
36. Braud, V. M. & McMichael, A. J. Regulation of NK cell functions through interaction of the CD94/NKG2 receptors with the nonclassical class I molecule HLA-E. Curr. Top. Microbiol. Immunol. 244, 85-95 (1999).
37. Park, S. H. & Bendelac, A. CDI-restricted T-cell responses and microbial infection. Nature 406, 788-792 (2000).
38. Moretta, A., Biassoni, R., Bottino, C., Mingari, M. C. & Moretta, L. Natural cytotoxicity receptors that trigger human NK-cell-mediated cytolysis. Immunol. Today 21, 228-234 (2000).
39. Wu, J. et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285, 730-732 (1999).
40. Cosman, D. et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14, 123-133 (2001).
41. Groh, V. et al. Broad tumor-associated expression and recognition by tumor-derived γ δ T cells of MICA and MICB. Proc. Natl Acad. Sci. USA 96, 6879-6884 (1999).
42. Nomura, M. et al. Genomic structures and characterization of Rael family members encoding GPI-anchored cell surface proteins and expressed predominantly in embryonic mouse brain. J. Biochem. (Tokyo) 120, 987-995 (1996).
43. Gatti, R. A. & Good, R. A. Occurrence of malignancy in immunodeficiency diseases. A literature review. Cancer 28, 89-98 (1971).
44. McClain, K. L. Immunodeficiency states and related malignancies. Cancer Treat. Res. 92, 39-61 (1997).
45. Cannon, M. & Cesarman, E. Kaposi's sarcoma-associated herpes virus and acquired immunodeficiency syndrome-related malignancy. Semin. Oncol. 27, 409-419 (2000).
46. Paller, A. S. Immunodeficiency syndromes. X-linked a γglobulinemia, common variable immunodeficiency, Chediak-Higashi syndrome, Wiskott-Aldrich syndrome, and X-linked lymphoproliferative disorder Dermatol. Clin. 13, 65-71 (1995).
47. Otley, C. C. & Pittelkow, M. R. Skin cancer in Liver Transplant recipients. LiverTranspl. 6, 253-262 (2000).
48. Aguilar, L. K., Rooney, C. M. & Heslop, H. E. Lymphoproliferative disorders involving Epstein-Barr virus after hemopoietic stem cell transplantation. Curr. Opin. Oncol. 11, 96-101 (1999).
49. Haliotis, T., Ball, J. K., Dexter, D. & Roder, J. C. Spontaneous and induced primary oncogenesis in natural killer (NK)-cell-deficient beige mutant mice. Int. J. Cancer 35, 505-513 (1985).
50. Gershwin, M. E., Ohsugi. Y., Castles, J. J., Ikeda, R. M. & Ruebner, B. Anti-mu induces lymphoma in germfree congenitally athymic (nude) but not in heterozygous (nu/+) mice. J. Immunol. 131, 2069-2073 (1983).
51. Shultz, L. D. et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J. Immunol. 154, 180-191 (1995).
52. Dighe, A. S., Richards, E., Old, L. J. & Schreiber, R. D. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN γ receptors. Immunity 1, 447-456. (1994).
53. Kaplan, D. H. et al. Demonstration of an Interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc. Natl Acad. Sci. USA 95, 7556-7561 (1998).
54. Van den Broek, M. F. et al. Decreased tumor surveillance in perforin-deficient mice. J. Exp. Med. 184, 1781-1790 (1996).
55. Street, S. E., Cretney, E. & Smyth, M. J. Perforin and interferon-γ activities independently control tumor initiation, growth, and metastasis. Blood 97, 192-197 (2001).
56. Smyth, M. J., Crowe, N. Y., & Godfrey, D. I. NK cells and NKT cells collaborate in host protection from MCA-induced fibrosarcoma. Int. Immunol. 13 (in the press, 2001).
57. Smyth, M. J. et al. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J. Exp. Med. 192, 755-760 (2000).
58. Smyth, M. J. et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 191, 661-668 (2000).
59. Shustov, A. et al. Role of perforin in controlling B-cell hyperactivity and humoral autoimmunity. J. Clin. Invest. 106, R39-47 (2000).
60. Matloubian, M. et al. A role for perforin in downregulatingT-cell responses during chronic viral infection. J. Virol. 73, 2527-2536 (1999).
61. Badovinac, V. P., Tvinnereim, A. R. & Harty, J. T. Regulation of antigen-specific CD8(+) T cell homeostasis by perforin and interferon-γ. Science 290, 1354-1358 (2000).
62. Davidson, W. F., Giese, T. & Fredrickson, T. N. Spontaneous development of plasmacytoid tumors in mice with defective fas-fas ligand interactions. J. Exp. Med. 187, 1825-1838 (1998).
63. Shaukaran, V. et al. IFN-γ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001).
64. Strander, H. & Einhorn, S. Interferons and the tumor cell. Biotherapy 8, 213-218 (1996).
65. Rossi, D. & Zlotnik, A. The biology of chemokines and their receptors. Annu. Rev. Immunol. 18, 217-242 (2000).
66. Ferrone, S. & Marincola, F. M. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol. Today 16, 487-494 (1995).
67. Elgert, K. D., Alleva, D. G. & Mullins, D. W. Tumor-induced immune dysfunction: the macrophage connection. J. Leukoc. Biol. 64, 275-290 (1998).
68. Walker, P. R., Saas, P. & Dietrich, P. Y. Tumor expression of Fas ligand (CD95L) and the consequences. Curr. Opin. Immunol. 10, 564-572 (1998).
69. Harding, C., Heuser, J. & Stahl, P. Endocytosis and intracellular processing of transferrin and colloidal gold-transferrin in rat reticulocytes: demonstration of a pathway for receptor shedding. Eur. J. Cell Biol. 35, 256-263 (1984).
70. Kurts, C. et al. Constitutive class I-restricted exogenous presentation of self antigens in vivo. J. Exp. Med. 184, 923-930 (1996).
71. Davis, I. D. An overview of cancer immunotherapy. Immunol. Cell Biol. 78, 179-195 (2000).
72. Tamura, Y., Peng, P., Liu, K., Daou, M. & Srivastava, P. K. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278, 117-120 (1997).
73. Melcher, A. et al. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nature Med. 4, 581-587 (1998).
74. Chiodoni, C. et al. Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response. J. Exp. Med. 190, 125-133 (1999).
75. Albert, M. L., Sauter, B. & Bhardwaj, N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392, 86-89 (1998).
76. Greten, T. F. & Jaffee, E. M. Cancer vaccines. J. Clin. Oncol. 17, 1047-1060 (1999).
77. Blachere, N. E. et al. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J. Exp. Med. 186, 1315-1322 (1997).
78. Sakaguchi, S. Animal models of autoimmunity and their relevance to human diseases. Curr. Opin. Immunol. 12, 684-690. (2000).
79. Sakaguchi, S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101, 455-458 (2000).
80. Hanninen, A. & Harrison, L. C. γδ T cells as mediators of mucosal tolerance: the autoimmune diabetes model. Immunol. Rev. 173, 109-119 (2000).
81. - (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J. Exp. Med. 187, 1047-1056 (1998).
82. Terabe, M. et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nature Immunol. 1, 515-520 (2000).
83. +T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163, 5211-5218 (1999).
84. Onizuka, S. et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res. 59, 3128-3133 (1999).
85. Seo, N., Tokura, Y., Takigawa, M. & Egawa, K. Depletion of IL-10- and TGF-β-producing regulatory γδ; T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells. J. Immunol. 163, 242-249 (1999).